Skip to main content
MUSTANG BIO, INC. logo

MUSTANG BIO, INC. — Investor Relations & Filings

Ticker · MBIO ISIN · US62818Q1040 LEI · 5493004W0VC1DPECQ779 US Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2017-08-21 Regulatory Filings
Country US United States of America
Listing US MBIO

About MUSTANG BIO, INC.

https://www.mustangbio.com/

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies. The company's primary focus is on translating medical breakthroughs into potential cures for difficult-to-treat cancers and rare genetic diseases. Its pipeline is centered on Chimeric Antigen Receptor (CAR) T-cell therapies, a form of immunotherapy. Mustang Bio's strategy involves in-licensing promising technologies from academic institutions and advancing them through clinical trials, supported by its in-house manufacturing capabilities to ensure the production and delivery of these advanced treatments.

Recent filings

Filing Released Lang Actions
8-A12B
Regulatory Filings Classification · 100% confidence The document is a Form 8-A filed with the SEC, which is used for the registration of certain classes of securities pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934. It includes details about the registration of common stock for listing on NASDAQ. The document is not a financial report, earnings release, or management discussion, but rather a regulatory filing related to securities registration. It is not an announcement of a report but the actual registration form. Therefore, it fits best under Regulatory Filings (RNS). The document length is 3364 characters, which is relatively short but contains the full registration form text, not just an announcement.
2017-08-21 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 14, 2017, by Mustang Bio, Inc. It reports the issuance of a press release announcing results of operations for the second quarter ended June 30, 2017. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes the press release as an exhibit. The length of the document is 3003 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'MENU VS MEAL' rule, this is an announcement of financial results, not the financial report itself. Therefore, the appropriate classification is Earnings Release (ER), which covers initial announcements of quarterly financial results (key highlights only).
2017-08-14 English
10-Q
Interim / Quarterly Report Q2 2017
2017-08-14 English
FORM 3/A
Director's Dealing
2017-07-21 English
FORM 3/A
Director's Dealing
2017-07-21 English
FORM 3
Director's Dealing
2017-07-21 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.